Lannett Announces Approval For Buprenorphine And Naloxone Sublingual Tablets, 2 mg/0.5 mg And 8 mg/2 mg

PHILADELPHIA, Sept. 20, 2016 — (Healthcare Sales & Marketing Network) — Lannett Company, Inc. (LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Buprenorphi… Biopharmaceuticals, Generics, FDA Lannett, Buprenorphine, Naloxone (Source: HSMN NewsFeed)